A Randomized, Controlled Trial on Dexmedetomidine for Providing Adequate Sedation and Preserved Neurologic Examination for Endovascular Treatment of Acute Ischemic Stroke or Cerebral Vasospasm.
Phase: PHASE2
Conditions: Stroke, Brain Ischemia, Vasospasm, Intracranial, Hemorrhage, Intracranial
Sponsor: University Hospitals Cleveland Medical Center

 
 
 
 
 
 
 
 
 
Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions 
 
NCT01845441 
 
November 1, 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Dex in Acute Stroke Intervention  
PI Blackham  
 
STUDY TITLE  
A Randomized, Controlled Trial on Dexmedetomidine for Providing Adequate Sedation and Preserved 
Neurologic Examination for Endovascular Treatment of Acute Ischemic Stroke or Cerebral Vasospasm.  
1.0 Protocol Overview  
1.1 Objective  
The purpose of this study is to evaluate the efficacy of Dexmedetomidine (Precedex) during acute 
endovascular ischemic stroke or subarachnoid hemorrhage induced cerebral vasospasm treatment for 
achieving a desired level of conscious sedation and its correlation with preserved neurological function.  
 
1.2 Study Design  
Prospective, randomized trial with patient and patient assessor blindness, consisting of one arm 
receiving Precedex for conscious sedation and the other arm receiving usual standard of care, which is 
either no sedation or, if necessary and as per clinician discretion, conventional conscious sedation with 
opioids and anxiolytics.  
 
1.3 Eligibility  
Subjects over the age of 18 with an ischemic stroke or cerebral vasospasm requiring endovascular 
intervention.  
 
1.4 Required sample size  
16 patients in each arm; total 32 patients.  
 
2.0 Abstract  
 
Precedex is a unique FDA-approved intravenous medication for conscious sedation in that it 
allows for “arousable” sedation, which is particularly appealing for use in patients with compromised 
neurologic function. While Precedex has been shown to be equivalent, if not superior to, conventional 
sedation in the procedural setting, it has not yet been evaluated in the setting of endovascular 
treatment of acute stroke and cerebral vasospasm. This setting is particularly ripe for evaluation, as 
there is currently controversy over the best method for management of patient sedation in light of the 
auxiliary need to preserve neurologic function. In order to evaluate the benefit of Precedex in this 
setting, it must be compared to the usual standard of care. Through our double blinded randomized 
trial, we will obtain information on the comparison between two arms, one receiving Precedex and the 
other the usual standard of care at our institution, for achieving and maintaining a pre-defined level of 
conscious sedation, while preserving baseline neurologic status. This assessment will optimistically serve 
as the basis for future large-scale studies and ultimately to the establishment of Precedex as a first-line 
sedative in the management of acute stroke patients undergoing endovascular intervention. 
 
 

3.0 Background and Significance  
Randomized trials have shown that endovascular therapy in the setting of a severe acute stroke has 
proven effective for large vessel occlusion (1). Several clinical studies demonstrate that multimodal 
endovascular therapy (pharmacologic agents and the use of various thrombectomy devices) leads to 
successful recanalization in patients with an acute ischemic stroke (2-5). 
 Patients with SAH commonly present with change in mental status such as drowsiness or confusion and 
can have neurologic deficits, which are graded according to severity by the Hunt and Hess scale (below). 
Similarly to stroke patients, these deficits can be exacerbated from sedation with anxiolytics and pain 
medication.  
HUNT and HESS SUBARACHNOID HEMORRHAGE SCALE of SEVERITY, 1968  
Grade  Signs and symptoms   
 
 
 
 
Survival  
1  
Asymptomatic or minimal headache and slight neck stiffness  
70%  
2  
Moderate to severe headache; neck stiffness;  
no neurologic deficit except cranial nerve palsy   
 
60%  
 
3  
Drowsy; minimal neurologic deficit  
 
 
 
50%  
 
4  
Stuporous; moderate to severe hemiparesis;  
possibly early decerebrate rigidity and vegetative disturbances  20%  
 
5  
Deep coma; decerebrate rigidity; moribund  
 
 
10%  
 
Patients with SAH have high risk for developing complications such as vasospasm. Cerebral vasospasm 
consists in vessel constriction that reduces blood flow and can lead to brain ischemia and stroke, if 
untreated. All SAH patients are monitored closely in the neuroscience ICU for at least 14 days following 
the rupture of their aneurysm, which is the time frame for which they are a greatest risk for cerebral 
vasospasm. Patients are suspected of having cerebral vasospasm if velocities are elevated on daily 
screening transcranial Doppler (TCD) studies or if there is a change in neurologic status. Prompt imaging 
evaluation of the intracranial vascular tree is necessary in order for accurate diagnosis and 
management. Cerebral angiography is preferable as it allows for simultaneous diagnosis and treatment.  
 
As with any patient, sedation is commonly employed during angiography for SAH patients, however, 
adequate sedation is particularly important in this situation for two reasons: first, these patients are 
more frequently agitated and combative and second, they are likely to undergo treatment (medication 
infusion) which puts them at higher risk for angiographic complications. As with stroke patients, it is 
preferable that the level of sedation allows them to be aroused easily enough to have their neurological 
status assessed during the procedure.  
 
Across North America and Europe, interventional neuroradiology practices are highly variable with 
regard to the use of sedation or anesthesia in vascular and interventional procedures (6). The reason for 
this high variability is that there are clearly illustrated benefits to both practices. The benefits of no 
sedation or moderate conventional sedation include the preservation of the neurologic examination, 
reduced time delay for commencement of the procedure and lower rates of hemodynamic changes (7). 

Neurologic testing during the procedure is important because it can reveal symptom resolution or 
progression which will affect how the procedure is continued (7). Disadvantages of no sedation include 
an increased level of consciousness in the patient which inevitably leads to increased patient movement, 
in general, and also as a response to pain, which can increase the technical difficulty of the case and lead 
to operator error. Disadvantages of moderate conventional sedation include the increased risk of 
hypoxemia and hypercapnia and an increased risk of aspiration due to an unprotected airway as well as 
a compromised neurologic exam (8-9). Proponents of anesthesia argue that an immobile patient allows 
for better image quality and better intra-procedural blood pressure control, as well as reduction in 
iatrogenic vessel injury (9-10). Disadvantages of anesthesia are an inability to monitor neurologic status, 
increased time delay for commencement of the procedure, and the risks associated with endotracheal 
intubation and extubation, which include increased intracranial pressure and hypotension (8-9). 
 
Dexmedetomidine hydrochloride (trade name Precedex) is a potent and highly selective central alpha 2-
adrenoreceptor agonist that is used therapeutically as a sedative. It was approved by the U.S. Food and 
Drug Administration in 1999 as an intensive care unit (ICU) sedative. The downstream action of the drug 
is decreased sympathetic activity due to diminished release of catecholamines in the locus coeruleus of 
the brainstem (11). Animal models have shown it to induce a dose-dependent decrease in activity, 
increase in sedation, and dose-dependent increase in time of being free from pain (12). Approved for 
use in the ICU, this drug is enjoying immense popularity in the critical care setting (13). It is used as a 
short term sedative in patients who are intubated and mechanically ventilated, particularly for imaging 
studies and for weaning patients off the ventilator. It offers a low risk of respiratory depression and 
increased hemodynamic stability during this period as compared to other sedatives (14). It is also unique 
as a sedative because it allows for arousable sedation (11). It has been especially efficacious in the 
neurologic ICU as studies have shown that it can improve long-term brain function in patients who are 
critically ill. The neuroprotective properties conferred by the drug include its ability to preserve sleep 
architecture and ventilatory drive (15). Studies also show that it does not compromise cognition or 
impair intellectual function, thus accurate patient neurologic status can continuously be obtained while 
on this drug (16). The risks associated with using Precedex are low, but there is a recognizable risk of 
hypotension and bradycardia, especially in patients with a history of hypotension. Because of its dual 
role as an analgesic and a sedative with low risks of respiratory depression, much interest has been 
generated in extending the use of this drug outside of the ICU setting and studies have shown it to be as 
efficacious at sedation as propofol and Midazolam, while still maintaining a much lower risk of 
respiratory depression. (17-19).  
 
4.0 Study Objectives  
 
The primary objective of this study is to compare the efficacy of Precedex versus usual standard of care 
in the setting of endovascular treatment of acute stroke or cerebral vasospasm by assessment of the 
following outcome measure:  
1. Comparison of number of “events” (as defined by any movement by subject during the 
procedure that delays or adversely affects the performance of the procedure in a safe and 
timely manner; See Appendix 13.3 for definition) in the Precedex arm versus the control 
arm. This will be measured as the proportion of one-minute intervals during the procedure 
in which an event occurred. 
 
The secondary objectives of this study include the preservation of the neurological exam and ability to 
stay within a specified sedation target in the Precedex group. These objectives will be evaluated with the 
following outcome measures:  

1. Measurement of the modified National Institutes of Health Stroke Scale (mNIHSS) score (See 
Appendix 13.2 for definition) at baseline and five times after the start of the procedure.  
2. Measurement of the Richmond Agitation-Sedation Scale (RASS) score (See Appendix 13.1 for 
definition) at baseline and every 20 minutes after the start of the procedure and at every time a NIH 
stroke score is obtained.  
 
The secondary objectives of this study also include collection of the following data and comparison 
across arms (see Appendix 13.3 for definitions):  
1. Estimation of the proportion of patients with preserved neurologic exam in the Precedex arm 
versus the control arm.  
2. Mortality and symptomatic hemorrhage rates.  
3. Peri-procedural complications.  
4. Recanalization time.  
5. Use of additional sedatives.  
 
We will also explore associations between motion related events and status of preserved neurologic 
exam with these outcomes.  
 
5.0 Research Design and Methods  
 
5.1 Study Design  
This is a prospective, randomized trial with patient and patient assessor blindness, investigating the 
ability of Precedex during acute endovascular ischemic stroke or cerebral vasospasm treatment to 
provide adequate conscious sedation with preserved neurological function. 32 subjects with diagnosis of 
acute ischemic stroke or cerebral vasospasm will be included in this study. 16 subjects will be 
randomized to the Precedex arm and 16 subjects will be randomized to the control arm. Eligible subjects 
will be those over 18 with acute ischemic stroke or cerebral vasospasm requiring endovascular 
intervention. The treating physicians and nurses will not be blinded to the treatment arm. However, the 
research nurse/patient assessor will be blinded to the study in its entirety except for the measures 
he/she is instructed to obtain.  
 
Drug Administration  
Dexmedetomidine arm: Precedex will be started after randomization and prior to arterial intervention 
and will be stopped at the end of the procedure. The Precedex will be used for an average of 90 
minutes; minimum duration of procedure is 30 minutes and maximum duration 4 hours. The Precedex 
will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If the heart rate is greater 
than 80 beats per minute and blood pressure greater than 120/70, a full loading dose (1.0 mcg/kg/hour) 
will be administered over 10 minutes. If heart rate is between 60 and 80 or systolic pressure between 90 
and 120, or the patient is greater than 65 years of age, a reduced loading dose of 0.5 mcg/kg will be 
given over 10 minutes. If there is no evidence of volume overload by physical examination, 500mL of 
colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate, in the absence of 
contraindications to glycopyrrolate, such as a history of glaucoma. Every 10 minutes, Precedex will be 
titrated by 0.1 mcg/kg/hour with the goal of achieving and maintaining RASS of 0 to -1. Additional 
Fentanyl and Midazolam intravenous bolus doses may be used, as per clinician discretion. Every 20 
minutes, a full RASS score will be assessed and, also, if at any time point during the procedure it is 
noticed that patient is at a level of moderate or deep sedation (RASS of -2 to -4) that cannot to be 
attributed to stroke or cerebral vasospasm in evolution itself or to procedure related complication, then 
Precedex will be titrated to a lower dose.  

 
Control arm: Our usual standard of care is to attempt the intervention without sedation. As per 
attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be 
used to control aggressive patient movement that adversely affects the technical capacity of the 
procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients 
will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.  
 
For the purposes of ensuring blindness of the research nurse/patient assessor, the treating physicians 
and nurses will be instructed to communicate in terms of administering or adjusting “the sedative 
medication”, and the actual details of any medication adjustment will be discussed out of hearing range 
of the research nurse/patient assessor.  
 
All subjects will be closely monitored by the radiology nurse during the procedure for hypotension, 
bradycardia and oxygenation saturation.  
 
Primary Outcome – Number of ‘Events’ (see Appendix 13.3 for definition)  
Continuous monitoring by the research nurse/patient assessor will be done to evaluate for patient 
movements by the subject that delay or adversely affect the performance of the procedure in a safe and 
timely manner (an ‘event’). If the subject has such a movement, then it will be considered an event. One 
minute interval between patient event assessments will be given to prevent subjective bias. After every 
one minute, it will be determined if an event has occurred. Over the length of the procedure, the total 
number of one-minute intervals with an event occurrence will be summed. In turn, this summed value 
will be divided by the total number of minutes in the procedure, so that we obtain a standardized value 
as the primary outcome measure. This ratio is the proportion of oneminute intervals with events during 
the procedure, which allow for direct comparison of values across procedures of varying length. This 
outcome measure employs short observation intervals for counting events to encourage more precise 
measurement. At the same time, this approach will be more systematic and more easily replicable than 
counting events directly, which requires interpretation as to when a movement event begins and ends, 
which can be difficult and more subjective.  
 
Secondary Outcome -- Preserved Neurologic Exam  
Dexmedetomidine arm: Neurologic status using the modified NIHSS scale (mNIHSS, see Appendix 13.2) 
will be assessed five times: 1) in the emergency room, 2) prior to the start of the procedure, 3) one time 
at a convenient moment during the procedure (usually after some revascularization has occurred), 4) at 
the conclusion of the procedure, 5) 1-2 hours after the conclusion of the procedure. RASS score will also 
be concomitantly assessed with each preserved neurologic exam assessment. The observed proportion 
of times out of the 5 trials after the start of the procedure that neurologic exam is preserved during a 
procedure will be a secondary outcome of this study.  
 
If clinical worsening of subject of mNIHSS >4 at any time point during the procedure is noticed with the 
level of sedation of RASS score of 0 to -1 that cannot to be attributed to stroke in evolution itself or to 
procedure related complication, then administration of Precedex will be stopped and patient will be 
reexamined at 15 minute intervals until patient returns to baseline mNIHSS or change in mNIHSS can be 
attributed to stroke or cerebral vasospasm in evolution or procedure related complication, or any other 
physiologic compromise.  
 
Control arm: Neurologic status using the mNIHSS scale will be assessed five times for this arm as well: 1) 
in the emergency room, 2) prior to the start of the procedure, 3) one time at a convenient moment 

during the procedure (usually after some revascularization has occurred), 4) at the conclusion of the 
procedure and 5) 1-2 hours after the conclusion of the procedure. If clinical worsening of subject of NIH 
>4 at any time point during the procedure is noticed that cannot to be attributed to stroke in evolution 
itself or to procedure related complication then subject will not receive any additional Midazolam or 
Fentanyl and patient will be reexamined at 15 minute intervals until the patient comes back to baseline 
mNIHSS or change in NIHSS can be attributed to stroke or cerebral vasospasm in evolution or procedure 
related complication, or any other physiologic compromise.  
 
 
Secondary Outcome – Maintaining Sedation Target  
Dexmedetomidine arm: RASS score will be determined at baseline and then every 20 minutes by the 
patient assessor. The clinical judgment of the treating physician will determine if Precedex will be 
titrated by 0.1 mcg/kg/hour with the goal of achieving and maintaining RASS of 0 to -1. Control arm: 
RASS score will be determined at baseline and then every 20 minutes. There will be no medication given 
or adjusted based on the RASS score. Medications will be administered at clinician discretion. The 
number of events and mNIHSS will be scored and recorded by a clinical research nurse/patient assessor 
who will be blinded to the study protocol in its entirety with the exception of the data to be acquired as 
noted above, and with the exception of the 3 hour post-procedure mNIHSS, which will be obtained by 
the NSICU nurse as per standard of care. The research nurse will be from a pool of nurses who are 
trained in the use of the RASS and mNIHSS. The research nurse will be on call and contacted by the 
interventional fellow or attending as soon as he/she becomes aware of the possibility of the 
interventional management of an acute stroke. Clinical judgment by the treating physician and nurses 
will be used to determine the level of sedation (RASS score) in order to make titration decisions in the 
Dexmedetomidine arm. Data entry will be done performed by the research assistant on the day 
following the procedure. Subsequent to the patient discharge, data extraction from follow-up clinical 
and imaging data regarding mortality, symptomatic hemorrhage rates and peri-procedural 
complications will be collected by the research assistant. 5.2 Reference Standard The reference standard 
or control group will receive the usual standard of care at our institution. For the majority of patients, 
this means no sedation at all. In the case of a patient in the range of agitation which corresponds to a +3 
or higher on the RASS, it is likely that the patient will receive the minimum combination of Midazolam 
and Fentanyl, as per attending physician discretion.  
 
5.3 Investigator and Institutional Requirements  
All investigators participating in this clinical trial are qualified and certified to conduct clinical trials 
involving humans according to our institutional regulations. UniversityHospitals of Cleveland, 
Department of Radiology, has access to a research coordinator, statistical support (as listed above), a 
medical writer, an IRB committee, a pharmacy with support from a dedicated neuro-pharmacist (as 
listed above), a laboratory, and a contracts and legal department. We have access to a patient clinic in 
conjunction with the Department of Neurosurgery.  
 
5.4 Subject Eligibility Criteria  
 
Screening criteria  
All acute stroke or cerebral vasospasm patients referred for endovascular intervention will be screened 
by study investigators for enrollment in this study. The study investigators will clinically evaluate the 
patient to assess the need for sedation during the procedure. Level of sedation (RASS score) will be used 
to screen the patients (See 13.1).  
 

Inclusion Criteria  
1. Patients with acute ischemic stroke who require endovascular intervention between the ages 
of 18 and 85, in whom a mNIHSS score can be obtained.  
2. Patients with subarachnoid hemorrhage who are referred to cerebral angiography for 
suspicion for vasospasm between the ages of 18 and 85, in whom a mNIHSS score can be obtained. 
 
Exclusion Criteria  
Subjects presenting with any of the following will not be included in the study:  
1. History of severe hepatic disease or severe renal disease (GFR <20). 
2. Hemodynamic instability. 
3. Pregnancy.  
4. Known allergy to study drug.  
5. Evidence or history of cardia electrophysiology instability including uncontrolled 
hemodynamically unstable complex atrial/ventricular arrhythmia or conduction block at the time of 
evaluation with the exception of atrial fibrillation, and heart rate less than 60 systolic blood pressure less 
than 90.  
6. Respiratory compromise requiring intubation. 
7. Any medical (including history of cardiac conduction block, major hepatic or renal disease) or 
laboratory abnormality that may increase the risk associated with the trail participation or drug 
administration or may interfere with interpretation of trail results.  
8. Baseline continuous infusion of sedative.  
 
Recruitment Precedure 
The neurointerventional attending physician or fellow will approach the patient or legally authorized 
representative to explain the aims, risks and benefits of this study. Informed consent will be obtained 
from the subjects or legally authorized representative. Eligible subjects who have given their consent 
will be enrolled in this study (See 13.4 Appendices). 
 
5.5 Study Calendar/Schedule  
All drug administration takes place within a 6 hour time frame and there will be no return or follow-up 
visits. As per review of our database, 32 subjects should be enrolled within 9-12 months of contract 
execution, at the rate of 2-4 per month. This would require 1-2 vials of Precedex per month. One-half of 
the patients should be enrolled by 6 months and all of the subjects by one year from contract execution. 
At conclusion of the trial, the manuscript should be completed by 14 months from contract execution 
and sent to Hospira for review. 
 
5.6 Accrual Goals and Monitoring  
According to statistical power analysis, an overall study population size of at least 32 patients is required 
to achieve primary objectives. According to prior retrospective data, this number will be achieved at 
approximately one year after initiation of the study. After 6 months and one year, the study population 
size recruited up to such time point will be assessed.  
 
5.7 Randomization  
32 subjects with diagnosis of acute ischemic strokes or cerebral vasospasm will be included in this study. 
16 patients will be enrolled in the Precedex arm and 16 patients will be enrolled in the control arm. All 
subjects who have met all inclusion criteria and no exclusion criteria and are eligible to receive study 
drug will be randomized. The patients will be randomized in both groups by using a shuffle card 
technique. The subject will be blinded to the treatment arm to which they were randomized. The 

neurointerventionalist team who will be performing the interventional procedure will be informed of 
the treatment arm. 
 
5.8 General Concomitant Medication and Supportive Care Guidelines  
Sedatives: It is well documented that dexmedetomidine has a dose sparing effect when used 
concomitantly with other medications used for sedation and analgesia. If deemed necessary, 
supplemental sedatives (opioids or benzodiazepines) will be utilized at lower doses and the dosing 
interval will be limited to 10 minutes between repeated dosing. Antihypertensives: If antihypertensive 
therapy is necessary, dosing will be consistent with current practice, and the dosing interval will be 
limited to 10 minutes between repeated dosing and dose titrations for these agents. Typical 
Medications: Opioids: Fentanyl; Anxiolytic: Midazolam; Antihypertensive: Labetalol, Hydralazine, and 
Nicardipine  
 
5.9 Post-therapy Visits  
No further visits are part of this trial. 
 
5.10 Criteria for Removal from Study  
At all times the patient can withdraw from this study and receive the usual standard of care. If any of the 
clinical scenarios detailed in the exclusion criteria occur or are discovered, the patient will be removed 
from the study.  
 
6.0 Statistical Considerations  
 
Procedures will last on average 90 minutes, and a minimum of 30 minutes. We expect all subjects to 
complete the procedure.  
 
For first aim: In projecting the available power from the proposed design, we expect that at least 30% of 
subjects in the control arm will eventually be given Midazolam and/or Fentanyl. We conservatively 
project that if no Midazolam and/or Fentanyl are administered, there will be on average at least 24 one-
minute intervals with a recorded motion event during an average length procedure of 90 minutes, and 
no events will occur if Midazolam and/or Fentanyl are administered. In other words, we expect a 
proportion of 0.2667 of the one-minute intervals during a procedure to have events. Given our 
preliminary experience with Precedex, only 2 out of 13 subjects recorded a motion event at all during 
procedure. For those that did, 10-12 events were observed. 
 
Anticipated Results: Hence, for the usual care arm, the expected number of events in a 90-minute 
period is 16, given the assumption that 30% receive Midazolam and/or Fentanyl. Equivalently, suppose 
an expected proportion of 0.267 of the one-minute intervals will have events. For the Precedex arm, 
suppose conservatively that the expected number of one-minute intervals with events in a 90-minute 
period is 8; equivalently, suppose the expected proportion of one-minute intervals that will have events 
is 0.089. A common assumption for count data within a given time period is that they follow a Poisson 
distribution. The characteristic of the Poisson distribution that is of interest for this power analysis is 
that the mean and variance are equal. Being conservative, suppose that the variance is four times as 
large as the mean, and larger than we expect. Note that a hypothesis test to see if the expected number 
of one-minute intervals with events in a given time period (equivalently, the expected proportions) are 
equal between Precedex and usual care arms, at two-sided Type I error of 0.05, will have power equal to 
0.885 using a two-sample t-test. Hence, we believe that the study should easily have sufficient power for 
this aim. A nonparametric Mann Whitney test also will be considered. 

 
We will assess correlation between intervals, as the power analysis assumes independent observations. 
Impact of this assumption will be assessed through fitting a generalized linear mixed model that allows 
for correlated binary outcomes, and analysis of a treatment effect in the context of that model will be 
compared with the t-test results. Treatment arm will be denoted by a binary variable, and the 
corresponding coefficient will be tested to see if it is zero or not. We will assess different covariance 
structures, and explore including time of interval as a covariate. While we do not expect strong intra-
subject serial correlation, presence of correlation would have some effect on power, so it is prudent to 
be conservative with a larger sample size than is needed to obtain power of 0.80 under the 
independence assumption for the t-test. The required sample size is actually 13 per arm to attain of 
power of 0.80, while we have proposed to collect samples of 16 per arm. Moreover, we also assumed 
that the variances are four times the value of the projected mean. These variance values reflect 
overdispersion that may occur due to correlated observations, relative to the reference Poisson 
distributions that were described. Hence, in computing required sample size, we have tried to be 
conservative in order to account for possible correlation. The projected sample size requirement should 
provide adequate power under small serial correlation as well. Note also that we will have a very large 
number of observations over time per subject (on average, around 90 one-minute intervals), which 
should enhance power for detecting treatment differences in the mixed model. SPSS has a mixed 
models package that we will employ. 
 
An alternative analytic approach that was considered is the use of contingency table analysis. Treatment 
arms could comprise two rows, and the columns could represent categories associated with counts of 
events. However, due to the relatively small projected sample size, the number of categories 
representing count number of one-minute intervals with an event would have to be restricted in order 
for each cell to have sufficient number of counts for asymptotic Chi-square analysis to be applicable. 
This may well reduce observed variability between treatment arms, and hence we believe the proposed 
approach of comparing these counts through two-sample comparison methods of means (or medians) is 
preferable and more powerful.  
 
For the secondary analyses: It will be of interest to determine if capability for neurological exam peri 
and post procedure is preserved. We will count the number of exams for which capability is preserved, 
out of the 5 exams conducted for each subject once the procedure has begun. We will estimate and 
report 95% confidence intervals for the proportion of preserved exams per procedure for subjects who 
are administered Precedex. We expect that at worst, based on our preliminary experience with 
Precedex, that for subjects in the Precedex arm, at least 60% to 80% of exams will have such capability 
preserved. Hence, we expect confidence interval half-widths to be between 0.240 and 0.196. For the 
control arm, we expect that those receiving Midazolam and/or Fentanyl will not have neurologic exam 
preserved, while those who do not will have all of their exams preserved. Hence, on average, we expect 
around 75% of exams to be preserved in the control arm. We will also estimate 95% confidence intervals 
for the respective proportion for this group, which should have similar interval lengths as for the 
Precedex group, as well as compare proportions between these groups using two-sample z-test. We do 
not expect to find statistically significant differences. Another secondary outcome of interest that will be 
analyzed similarly is the proportion of RASS exams for each subject that are in a bandwidth of 0 to -1. 
We will statistically compare the respective averages of the proportions across arms as well. Finally, we 
will also compare secondary outcomes across arms for mortality and symptomatic hemorrhage rates, 
peri-procedural complications, recanalization time, and use of additional sedatives. 
 
7.0 Adverse Events  

 
7.1 Definition.  
A serious adverse event (SAE) is defined as any untoward medical occurrence that: (1) results in death, 
or (2) is life-threatening (at the time of the event), or (3) requires inpatient hospitalization or 
prolongation of an existing hospitalization, or (4) results in persistent or significant disability or 
incapacity, or (5) is a congenital anomaly/birth defect.  
 
Abnormal results of diagnostic procedures are considered to be adverse events (AEs) if the abnormality: 
(1) results in study withdrawal (2) is associated with a serious adverse event (3) is associated with clinical 
signs or symptoms (4) leads to additional treatment or to further diagnostic tests (5) is considered by 
the investigator to be of clinical significance. 
 
7.2 Adverse Event Grading:  
Grade is used to denote the severity of the adverse event.  
1 – Mild  
2 – Moderate  
3 – Severe  
4 – Life-threatening or disabling  
5 – Fatal 
 
Adverse Event Attribution: Attribution is used to determine whether an adverse event is related to a 
study treatment or procedure.  
 
Attribution categories are:  
Definite – AE is clearly related to the study treatment or procedure.  
Probable – AE is likely related to the study treatment or procedure.  
Possible – AE may be related to the study treatment or procedure.  
Unlikely – AE is doubtfully related to the study treatment or procedure.  
Unrelated – AE is clearly NOT related to the study treatment or procedure. 
 
7.4 Expected Adverse Events  
Hypotension: Any decrease in blood pressure to <90Hg systolic or <60mm Hg diastolic will be considered 
hemodynamically unstable. At this time point medication will be titrated down to lower dose and 250cc 
normal saline intravenous fluid will be administered. Blood pressure will be re-evaluated in 3-5 minutes 
interval. If subject’s blood pressure still remains unchanged then medication will be stopped and subject 
will be treated with intravenous normal saline boluses and may need administration or additional 
vasopressors.  
 
Bradycardia: A decrease in heart rate to <60 beats per minutes from the subject’s baseline heart rate 
will be considered as bradycardia secondary to medication use. At this time point medication will be 
titrated down to lower dose. If subject heart rate still remains unchanged or interval decrease in heart 
rate is observed then medication will be stopped. Glycoprrolate or atropine via intra venous injection 
may be used to counteract drug-induced or vagal reflexes and their associated arrhythmias.  
 
Mortality and Morbidity: Any periprocedural death or morbidity that cannot be attributed to any other 
cause and if directly related to any adverse event mentioned in Precedex pharmaceutical manual as a 
side effect will be defined as mortality or morbidity secondary to medication use. 
 

7.4 Adverse Event Reporting  
It is the responsibility of the investigator to document all adverse events (AEs) which occur during the 
course of the study.  
 
8.0 Data Management; Administration  
 
In order to protect confidentiality the subject will be assigned an identification number. This number will 
be used on all data from the subject and will be used for documentation purposes. Data management 
for the optimal entry, processing, storage, and retrieval for this protocol's data will be accomplished by 
the principal investigator. The database will be located on a computer or in a locked cabinet in a locked 
office. This computer will be secured, accessible only by the research team. A second, secured, copy of 
the protocol data will be stored in a locked room accessible only by the research team. For quality 
control, auditing, and checking data for integrity, there will be a regular accounting of data periodically 
performed. 
 
9.0 Drug Quantity and Financial Expectations  
 
16 patients are expected to be enrolled in the Precedex arm, with one vial being required per patient, as 
well as 5 extra vials. The fixed Administrative and IRB costs would be expected as the initial payment. 
Otherwise, it is anticipated that payment will occur as the total divided quarterly or monthly. 
 
10.0 References  
 
1. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The 
PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 
1999;282:2003-11.  
2. Gupta R, Vora NA, Horowitz MB, et al. Multimodal reperfusion therapy for acute ischemic stroke: 
factors predicting vessel recanalization. Stroke 2006;37:986-90.  
3. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of 
the Multi MERCI trial. Stroke 2008;39:1205-12.  
4. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices 
for clot removal in intracranial large vessel occlusive disease. Stroke 2009;40:2761-8.  
5.Flaherty ML, Woo D, Kissela B, et al. Combined IV and intra-arterial thrombolysis for acute ischemic 
stroke. Neurology 2005;64:386-8.  
6. Haslam PJ, Yap B, Mueller PR, Lee MJ. Anesthesia practice and clinical trends in interventional 
radiology: a European survey. Cardiovasc Intervent Radiol 2000;23:256- 61.  
7.Abou-Chebl A, Lin R, Hussain MS, et al. Conscious sedation versus general anesthesia during 
endovascular therapy for acute anterior circulation stroke: preliminary results from a retrospective, 
multicenter study. Stroke 2010;41:1175-9.  
8.Varma MK, Price K, Jayakrishnan V, Manickam B, Kessell G. Anaesthetic considerations for 
interventional neuroradiology. Br J Anaesth 2007;99:75-85.  
9. Chamczuk AJ, Ogilvy CS, Snyder KV, et al. Elective stenting for intracranial stenosis under conscious 
sedation. Neurosurgery 2010;67:1189-93; discussion 94.  
10. Stoneburner JM, Nishanian GP, Cukingnan RA, Carey JS. Carotid endarterectomy using regional 
anesthesia: a benchmark for stenting. Am Surg 2002;68:1120-3.  
11. Hoffman WE, Kochs E, Werner C, Thomas C, Albrecht RF. Dexmedetomidine improves neurologic 
outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist 
atipamezole. Anesthesiology 1991;75:8-.  

12. Taiji K. [Dexmedetomidine hydrochloride (Precedex), a new sedative in intensive care, its 
pharmacological characteristics and clinical study result]. Nippon Yakurigaku Zasshi 2004;124:171-9. 
13. Keegan MT. Sedation in the neurologic intensive care unit. Curr Treat Options Neurol 2008;10:111-
25.  
14. Kemp KM, Henderlight L, Neville M. Precedex: is it the future of cooperative sedation? Nursing 
2008;38 Suppl Critical:7-8.  
15. Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anaesthesiol 2010.  
 
16. Mirski MA, Lewin JJ, 3rd, Ledroux S, et al. Cognitive improvement during continuous sedation in 
critically ill, awake and responsive patients: the Acute Neurological ICU Sedation Trial (ANIST). Intensive 
Care Med 2010;36:1505-13.  
17. Cata JP, Folch E. Dexmedetomidine as sole sedative during percutaneous carotid artery stenting in a 
patient with severe chronic obstructive pulmonary disease. Minerva Anestesiol 2009;75:668-71.  
18. David MD, De Marchi L. Dexmedetomidine sedation for awake tracheotomy: case report and 
literature review. J Clin Anesth 2010;22:360-2.  
19. Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedativeanalgesic agent. 
Proc (Bayl Univ Med Cent) 2001;14:13-21.  
20. Sessler CN, Gosnell M, Grap MJ, Brophy GT, O'Neal PV, Keane KA et al. The Richmond Agitation-
Sedation Scale: validity and reliability in adult intensive care patients. Am J Respir Crit Care Med 
2002;166:1338-1344  
21. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, Ringleb AP, Lorenzano S, 
Manelfe C, Bozzao L. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships 
with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I 
(ECASS I) cohort. Stroke. 1999; 30: 2280–2284